What is Generico?
Generico, operating under the Zeno Health brand, functions as a specialized healthcare provider dedicated to the democratization of medicine. The company addresses the critical market gap in India by providing affordable, high-quality generic alternatives to expensive branded pharmaceuticals. Through a combination of retail presence and public health education, Generico empowers consumers to make informed decisions regarding their medical expenditures. Its business model is fundamentally designed to lower the barrier to entry for essential healthcare, positioning the firm as a disruptive force in a market traditionally dominated by high-cost drug manufacturers and fragmented supply chains.
How much funding has Generico raised?
Generico has raised a total of $2.9M across 3 funding rounds:
Other Financing Round
$1.4M
Debt
$1.4M
Series A
$136K
Other Financing Round (2020): $1.4M with participation from Alteria Capital
Debt (2021): $1.4M led by Alteria Capital
Series A (2021): $136K supported by Alteria Capital
Key Investors in Generico
Alteria Capital
A prominent venture debt firm that provides specialized financing solutions to high-growth startups, focusing on companies with strong operational metrics and clear paths to profitability.
What's next for Generico?
With this recent infusion of capital, Generico is well-positioned to accelerate its expansion strategy. The company is expected to leverage these resources to deepen its penetration into Tier 2 and Tier 3 cities, where the demand for cost-effective healthcare solutions remains largely unmet. Future growth will likely focus on optimizing supply chain logistics and expanding its digital health platform to provide a more seamless experience for patients. As the firm transitions into a more mature phase of its lifecycle, the focus will shift toward achieving economies of scale and solidifying its brand equity as a trusted leader in the affordable medicine sector.
See full Generico company page
